15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer

Cancer Research

Volumn 66, Issue 15, 2006, Pages 7818-7823

  Wolf, Ido ^a   O'Kelly, James ^a   Rubinek, Tamar ^a   Tong, Min ^c   Nguyen, Anh ^a   Lin, Bryan T ^b   Tai, Hsin Hsiung ^c   Karlan, Beth Y ^a   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMI Tarzana Regional Medical Center   (United States)

^c University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; AROMATASE; ESTROGEN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ANIMALS; BASE SEQUENCE; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; RNA, SMALL INTERFERING; TRANSFECTION; UP-REGULATION;

EID: 33747873279     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4368     Document Type: Article

References (21)

1. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004;215:1-20.
2. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-6.
3. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-81.
4. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;2:632-5.
5. Richards JA, Petrel TA, Brueggemeier HW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol 2002;80:203-12.
6. Ensor CM, Tai HH. 15-Hydroxyprostaglandin dehydrogenase. J Lipid Mediat Cell Signal 1995;12:313-9.
7. Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 2004;101:17468-73.
8. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217-23.
9. +-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005;36:65-72.
10. Gee JR, Montoya RG, Khaled HM, Sabichi AL, Grossman HB. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol 2003;31:266-70.
11. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005;65:4218-27.
12. Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP. Down-regulation and growth inhibitory role of C/EBPα in breast cancer. Clin Cancer Res 2005;11:3184-90.
13. +-dependent 15-hydroxyprostaglandin dehydrogenase gene. J Mol Endocrinol 2003;31:105-21.
14. +-dependent 15-hydroxyprostaglandin dehydrogenase gene promoter is controlled by Ets and activating protein-1 transcription factors and progesterone. Endocrinology 2000;141:581-97.
15. Watt F, Molloy PL. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev 1988;2:1136-43.
16. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996;56:5125-7.
17. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
18. Tari AM, Simeone AM, Li YJ, Gutierrez-Puente Y, Lai S, Symmans WF. Cyclzooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. Lab Invest 2005;85:1357-67.
19. Brodie AM, Lu Q, Long BJ, et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 2001;79:41-7.
20. Diaz-Cruz ES, Shapiro CL, Braeggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005;90:2563-70.
21. Zahnow CA. CCAAT/enhancer binding proteins in normal mammary development and breast cancer. Breast Cancer Res 2002;4:113-21.